Affimed NV Logo Image

Affimed NV

Most Recent Annual Report

2018 Annual Report

Affimed NV

Affimed NV does not currently have any hardcopy reports on Click the button below to request a report when hardcopies become available.

Archived Annual Reports

  • Affimed NV
  • Affimed NV
  • Affimed NV

About Affimed NV

201-500 Employees
Based in Heidelberg, Germany

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol